Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1996-06-13
1999-11-02
Hutzell, Paula K.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
53038815, 53038822, 5303888, 5303873, 5303877, C07K 1630, C12P 2108
Patent
active
059773227
ABSTRACT:
This invention provides novel human antibodies that specifically bind to human c-erbB-2. In one embodiment, the antibodies are single chain antibodies initially developed by phage display against a c-erbB-2 target. The resulting antibodies (designated C6 antibodies) show improved specificity and affinity for c-erbB-2. In addition, since the C6 antibodies are both relatively small and fully human they are less immunogenic in humans than other (e.g., full-size or chimeric) anti-c-erbB-2 antibodies. The C6 antibodies may be used alone or as components of chimeric molecules that specifically target and deliver effector molecules to cells overexpressing c-erbB-2.
REFERENCES:
patent: 5169774 (1992-12-01), Frankel et al.
Huston, James S. et al., (1988) "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci., USA, 85:5879-5883.
Vallera, Daniel A., (1994) "Immunotoxins: Will Their Clinical Promise Be Fulfilled?", Blood, 83(2):309-317.
Trail, P.A. et al., (1993) "Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates", Science, 261:212-215.
Weiner, L.M. et al., (1989) "Phase I Evaluation of an Anti-Breast Carcinoma Monoclonal Antibody 260F9-Recombinant Ricin A Chain Immunoconjugate", Cancer Res., 49:4062-4067.
Riethmuller, G. et al., (1992) "Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers", Curr. Opin. Immunol., 4:647-655.
Brinkmann, U. et al., (1993) "A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin", Proc. Natl. Acad. Sci. USA, 90:547-551.
Colcher, D. et al., (1988) "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies", Cancer Res., 48:4597-4603.
Gallinger, S. et al., (1993) "Comparative Dual Label Study of First and Second Generation Antitumor-associated Glycoprotein-72 Monoclonal Antibodies in Colorectal Cancer Patients", Cancer Res., 53:271-278.
Adams, Gregory et al., (1993) "Highly Specific in Vivo Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single-Chain Fv1", Cancer Res., 53:4026-4034.
Hoogenboom, H.R. et al., (1992) "Building antibodies from their genes", Immunol. Rev., 130:41-68.
Marks, J.D. et al., (1991) "By-passing Immunization: Human Antibodies from V-gene Libraries Displayed on Phage", J. Mol. Biol., 222:581-597.
Marks, J.D. et al., (1992) "By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", Bio/Technology, 10:779-783.
Hawkins, R.E. et al., (1992) "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation", J. Miol. Biol., 226:889-896.
Reichman, L. et al., (1993) "Phage Display and Selection of a Site-Directed Randomized Single-Chain Antibody Fv Fragment for Its Affinity Improvement", Biochemistry, 32:8848-8855.
McCafferty, J. et al., (1990) "Phage antibodies: filmentous phage displaying antibody variable domains", Nature, 348:552-554.
Griffiths, A.D. et al., (1993) "Human anti-self antibodies with high specificity from phage display libraries", EMBO J., 12:725-734.
Clackson, Tim et al., (1991) "Making antibody fragments using phage display libraries", Nature, 352:624-628.
Group, E.B.C.T.C., (1992) "Systematic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy", Lancet, 339:1-15.
Allred, D.C. et al., (1992) "Overexpression of HER-2
eu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer", Hum. Path., 23:974-979.
Slamon, D.J. et al., (1987) "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene", Scienc, 235:177-182.
Carter, P. et al., (1994) "Towards and Immunotherapy for p185HER2 overexpressing tumors", Antigen & Antibody Engineering in Breast Cancer Diagnosis, pp. 83-94.
Shepard, H.M. et al., (1991) "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic", J. Clin. Immunol., 11:117-127.
Soderlind, Eskil et al., (1992) "Phase Display Technology in Antibody Engineering: Design of Phagemid Vectors and in vitro Maturation Systems", Immunological Reviews, 130:109-124.
Dsis et al (1994) Cancer Res. 54:16-20.
Borrebaeck (1989) J. Immunol. 123:157-165.
Marks James D.
Schier Robert
Bansal Geetha P.
Hutzell Paula K.
The Regents of the University of California
LandOfFree
High affinity human antibodies to tumor antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High affinity human antibodies to tumor antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High affinity human antibodies to tumor antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2137014